Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Repare Therapeutics Inc. (RPTX : NSDQ)
 
 • Company Description   
Repare Therapeutics Inc. is an oncology company. It utilizes genome-wide, CRISPR-enabled SNIPRx(R) platform to discover and develop targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's product pipeline includes RP-3500, which is in clinical stage. Repare Therapeutics Inc. is based in St-Laurent, Canada.

Number of Employees: 129

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.44 Daily Weekly Monthly
20 Day Moving Average: 74,349 shares
Shares Outstanding: 42.89 (millions)
Market Capitalization: $61.76 (millions)
Beta: 0.84
52 Week High: $4.29
52 Week Low: $0.89
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -3.36% -8.59%
12 Week 60.00% 34.23%
Year To Date 9.92% 2.96%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
7171 Frederick-Banting Building 2 Suite 270
-
St-Laurent,A8 H4S 1Z9
CAN
ph: 857-412-7018
fax: -
investor@reparerx.com http://www.reparerx.com
 
 • General Corporate Information   
Officers
Lloyd M. Segal - President and Chief Executive Officer
Thomas Civik - Chairman
Steve Forte - Executive Vice President; Chief Financial Officer
David Bonita - Director
Samarth Kulkarni - Director

Peer Information
Repare Therapeutics Inc. (CORR.)
Repare Therapeutics Inc. (RSPI)
Repare Therapeutics Inc. (CGXP)
Repare Therapeutics Inc. (BGEN)
Repare Therapeutics Inc. (GTBP)
Repare Therapeutics Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 760273102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 42.89
Most Recent Split Date: (:1)
Beta: 0.84
Market Capitalization: $61.76 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.49 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.45 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.49
Price/Cash Flow: -
Price / Sales: 0.90
EPS Growth
vs. Year Ago Period: -336.67%
vs. Previous Quarter: -5.97%
Sales Growth
vs. Year Ago Period: -96.45%
vs. Previous Quarter: -97.95%
ROE
06/30/25 - -
03/31/25 - -78.12
12/31/24 - -44.47
ROA
06/30/25 - -
03/31/25 - -67.11
12/31/24 - -38.44
Current Ratio
06/30/25 - -
03/31/25 - 7.42
12/31/24 - 6.77
Quick Ratio
06/30/25 - -
03/31/25 - 7.42
12/31/24 - 6.77
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -11,809.23
12/31/24 - -155.67
Book Value
06/30/25 - -
03/31/25 - 2.92
12/31/24 - 3.56
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©